Pacific Biosciences Of California (PACB) Debt to Equity (2010 - 2023)

Pacific Biosciences Of California's Debt to Equity history runs 13 years deep, the most recent figure standing at $0.13 for Q3 2023.

• In Q3 2023, Debt to Equity changed N/A year-over-year to $0.13; the TTM figure through Sep 2023 stood at $0.13 (changed N/A YoY), while the FY2022 annual figure was $0.31, up 6105.92% from the prior year.
• Debt to Equity was $0.13 for Q3 2023 at Pacific Biosciences Of California, down from $0.29 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.31 in Q4 2022 to a low of $0.0 in Q4 2021.
• Historically, Debt to Equity has averaged $0.21 across 4 years, with a median of $0.28 in 2019.
• The sharpest annual moves came in 2019 and 2022: Debt to Equity jumped 123.86% in 2019, then soared 6105.92% in 2022.
• A 4-year view of Debt to Equity shows it stood at $0.29 in 2019, then plunged by 98.28% to $0.0 in 2021, then jumped by 6105.92% to $0.31 in 2022, then tumbled by 58.92% to $0.13 in 2023.
• The last three Debt to Equity figures came in at $0.13 (Q3 2023), $0.29 (Q2 2023), and $0.27 (Q1 2023), per Business Quant data.